Press Detail

/
PRESS RELEASE

Biotest increases revenues by 8,5%

- EBIT increase by 2,3%

- Good Progress in the R&D pipeline

- Revised outlook

Dreieich, August 11, 2014. The Biotest Group was again able to significantly increase revenues in the first half of 2014, recording growth of 8.5 % compared to the same period in the previous year. The Group generated revenues of EUR 264.1 million in the period under review compared to EUR 243.3 million for the same period in the previous year.

Rising research and development costs as well as the EUR 6.2 million decrease in the amount recognised in revenue on a pro rata basis under the percentage of completion method with regard to the upfront payment received from AbbVie and costs relating to the start of the expansion as part of "Biotest Next Level" resulted in only a moderate increase in operating profit (EBIT) from EUR 25.9 million to EUR 26.5 million (+ 2.3 %) despite the increase in sales. As outlined in the Annual report, the financial impact of the recall of the Bivigam^(R) lots has already been recognised in the financial year 2013. The recall and the competitive situation in the US market had a negative impact on the sales and earnings development in the first six months 2014. This effect will stay for the entire financial year. Despite the increased marketing of human albumin and the continuing internationalisation of the business and therefore the good business performance, the lower sales and profit contribution of Bivigam^(R) could not be compensated.

Whereas EBIT contributed by the Therapy segment increased substantially from EUR 13.7 million to EUR 20.6 million (+ 50.4 %), that of the Plasma & Services segment decreased by 40.0 % to EUR 7.5 million. This decrease was mainly attributable to the changed cost allocation, under which costs incurred are now directly allocated to this segment. Relevant costs incurred for process developments were charged on a pro rata basis for products and services of the Plasma & Services segment, which adversely impacted the earnings of this segment.

The financial result amounted to EUR - 4.8 million (same period in the previous year: EUR - 2.5 million). The capital measures successfully implemented in the past financial year were particularly evident in this regard. The fully placed loan note of EUR 210.0 million, amongst other things, gave rise to an increase in interest expense.

This resulted in earnings before taxes (EBT) of EUR 21.7 million for the Biotest Group compared to EUR 23.4 million for the same period in the previous year. Earnings after taxes (EAT) also decreased from EUR 15.3 million to EUR 13.8 million on an almost constant tax rate. Earnings per share were - also as a result of the increased number of shares by way of the capital increase - EUR 1.05.

Outlook:

The recall of Bivigam^(R) and the competitive situation in the US market will have a negative impact on the sales and earnings development for the full year 2014.

Due to the political crisis in Russia and Middle East further negative impacts on the operative business cannot be excluded.

Due to a positive development of clinical studies (i.e. enlargement of the clinical study IIb with tregalizumab (BT-061) including the accelerated production of clinical study material for a phase III study as well as accelerated production of additional clinical study material for Civacir^(R)) higher R&D expenses for the financial year 2014 are expected.

Based on the reasons given above, the Management Board revises its outlook. A sales increase in the range of 7 % and an operating result (EBIT) slightly above the previous year is expected. The business development of the Biotest Group for the 2014 fiscal year will continue to be assessed positively.

The half-year report can be downloaded from Biotest's website: http://www.biotest.de/ww/en/pub/investor_relations/publications/quarterly_reports.cfm

Biotest will hold a conference call for journalists and analysts tomorrow, 12.8.2014 at 10 a.m. CET.

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.000 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart